{
"id":"mk19_a_id_t66",
"number":66,
"bookId":"id",
"title":{
"__html":"Recommended Regimens for Initial Treatment of Most Persons with HIV Infection<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"326c9b",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 66. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t66"
}
]
},
"Recommended Regimens for Initial Treatment of Most Persons with HIV Infection",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"60a958",
"class":"cell txt l",
"children":[
"ART can be initiated before drug resistance testing and HLA-B*57:01 test results are available. In this setting, one of the following antiretroviral therapy regimens is recommended:"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e41e5",
"class":"cell txt li",
"children":[
"Bictegravir/tenofovir alafenamide/emtricitabine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"43d0dc",
"class":"cell txt li",
"children":[
"Dolutegravir with tenofovir",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
" plus emtricitabine or lamivudine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b0615c",
"class":"cell txt l",
"children":[
"Additional recommended regimens include:"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57088e",
"class":"cell txt li",
"children":[
"Dolutegravir/abacavir/lamivudine",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e0414",
"class":"cell txt li",
"children":[
"Dolutegravir/lamivudine",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b9d994",
"class":"cell txt li",
"children":[
"Raltegravir plus (emtricitabine or lamivudine) plus tenofovir",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Revised based on the 2018 International Antiviral Societyâ€“USA Panel guidelines and the 2019 Department of Health and Human Services guideline update. A sample for genotypic testing should be sent before ART initiation. Before initiating treatment in a person of childbearing potential, a pregnancy test should be performed. Before prescribing ART to a person of childbearing potential, please refer to the guideline for information (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://clinicalinfo.hiv.gov/en/guidelines",
"target":"_blank"
},
"children":[
"https://clinicalinfo.hiv.gov/en/guidelines"
]
},
")."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are two forms of tenofovir that are approved in the United States. TAF has fewer bone and kidney toxicities than TDF, whereas TDF is associated with lower lipid levels. Safety, cost, and accessibility are among the factors to consider when choosing between these drugs."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Only for patients who are HLA-B*57:01 negative and without hepatitis B virus coinfection (AI)."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Except in those with a pretreatment HIV RNA level >500,000 copies/mL, chronic hepatitis B virus coinfection, or before results of HIV genotyping are available."
]
]
}